MwanzoGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
$ 9.88
Baada ya Saa za Kazi:(0.00%)0.00
$ 9.88
Imefungwa: 12 Sep, 16:01:43 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 10.04
Bei za siku
$ 9.85 - $ 9.98
Bei za mwaka
$ 6.19 - $ 11.14
Thamani ya kampuni katika soko
8.64B USD
Wastani wa hisa zilizouzwa
elfu 807.76
Uwiano wa bei na mapato
19.25
Mgao wa faida
1.78%
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.89B | 4.03% |
Matumizi ya uendeshaji wa biashara | 394.25M | -5.69% |
Mapato halisi | 117.06M | 688.78% |
Kiwango cha faida halisi | 6.19 | 654.88% |
Mapato kwa kila hisa | 0.19 | 26.23% |
EBITDA | 414.24M | 13.12% |
Asilimia ya kodi ya mapato | 27.36% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 582.38M | -74.23% |
Jumla ya mali | 19.77B | -11.32% |
Jumla ya dhima | 12.17B | -13.05% |
Jumla ya hisa | 7.60B | — |
hisa zilizosalia | 679.77M | — |
Uwiano wa bei na thamani | 1.32 | — |
Faida inayotokana na mali | 4.29% | — |
Faida inayotokana mtaji | 4.91% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 117.06M | 688.78% |
Pesa kutokana na shughuli | 155.27M | -38.60% |
Pesa kutokana na uwekezaji | -107.65M | -107.98% |
Pesa kutokana na ufadhili | -181.41M | -405.19% |
Mabadiliko halisi ya pesa taslimu | -194.12M | -111.66% |
Mtiririko huru wa pesa | 67.94M | -95.81% |
Kuhusu
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
18 Nov 1940
Tovuti
Wafanyakazi
23,800
